These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12110039)

  • 1. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 7. Choice of erythropoiesis stimulating agent in ESRD.
    Fishbane S; Shah HH
    Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 9. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 10. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Korbet SM
    Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
    [No Abstract]   [Full Text] [Related]  

  • 12. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
    Eschbach JW
    J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
    [No Abstract]   [Full Text] [Related]  

  • 19. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 20. [Erythropoiesis stimulating agents in clinical practice].
    Niemczyk L; Dębowska M
    Wiad Lek; 2014; 67(3):413-5. PubMed ID: 25782201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.